Between @ and @ , @ women were enrolled in HIV Prevention Trials Network ( HPTN ) protocol @ , a phase II/IIb evaluation of the safety and effectiveness of BufferGel and PRO @ for prevention of STIs , including Neisseria gonorrhoeae ( NG ) , Chlamydia trachomatis ( CT ) and Trichomonas vaginalis ( TV ) .